BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.

Front Oncol · 2023 · PMC10421724 · PMID 37576888

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not with statistically significant difference, BAT6026 showed a trend of stronger anti-tumor effect in the OX40-humanized mice model than BAT6026-wt (TGI 38.3% versus 21.1%) (data not shown).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.